Radionetics Oncology
Founded 2021 · CIK 0001989304 · Biotech · Private
Precision radiopharmaceutical drug candidates for oncology treatment
radionetics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $54M
- 1 Form D · Aug 2023
- 38 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 36
- 2 granted · 34 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $54,211,759 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2515 | Alligator Bioscience AB (publ) | — | $10M |
| 2516 | Prosetta Biosciences Inc. | — | $31M |
| 2517 | Metselex, Incorporated | — | — |
| 2518 | Radionetics Oncology | — | $54M |
| 2519 | SIVEC BIOTECHNOLOGIES, INC. | — | $3.3M |
| 2520 | MOUNTAIN VALLEY MD INC. | — | $18M |
| 2521 | Botanix Pharmaceuticals Ltd. | — | $20M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dan EstesDirector · Executive Officer
- Brett EwaldExecutive Officer
- Umesh GangadharmathExecutive Officer
- Ana KusnetzowExecutive Officer
- Istvan MolnarExecutive Officer
- Andrew SchwabDirector
- Scott StruthersDirector
- Yunfei ZhuExecutive Officer
Patents
- Neurotensin Receptor 1 (NTSR1) Targeted Therapeutics And Uses Thereofapplication
- Neuropeptide Y1 Receptor (NPY1R) Targeted Therapeutics And Uses Thereofgranted
- Follicle-stimulating Hormone Receptor (fshr) Targeted Therapeutics And Uses Thereofapplication
- GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOFapplication
- Kisspeptin Receptor (KISS1R) Targeted Therapeutics And Uses Thereofgranted
- Neuropeptide Y1 Receptor (NPY1R) Targeted Therapeutics And Uses Thereofapplication
- Non-peptide Targeted Therapeutics And Uses Thereofapplication
- Neuropeptide Y1 Receptor (NPY1R) Targeted Therapeutics And Uses Thereofapplication
- Melanocortin Type 2 Receptor (MC2R) Targeted Therapeutics And Uses Thereofapplication
- Kisspeptin Receptor (KISS1R) Targeted Therapeutics And Uses Thereofapplication
- Kisspeptin Receptor (KISS1R) Targeted Therapeutics And Uses Thereofapplication
- Neuropeptide Y1 Receptor (NPY1R) Targeted Therapeutics And Uses Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.